Automatic Micro Needle System (CODE-X)

K252591 · Woorhi Mechatronics Co., Ltd. · QAI · May 13, 2026 · General, Plastic Surgery

Device Facts

• Record ID: K252591
• Device Name: Automatic Micro Needle System (CODE-X)
• Applicant: Woorhi Mechatronics Co., Ltd.
• Product Code: QAI · General, Plastic Surgery
• Decision Date: May 13, 2026
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4430
• Device Class: Class 2
• Attributes: Therapeutic

Indications for Use

The Automatic Micro Needle System (CODE-X) is a microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older.

Device Story

Motorized, AC-powered microneedling device; creates microscopic channels in epidermal/upper dermal skin layers. System comprises reusable handpiece with embedded microprocessor control and sterile, single-use 12-pin or 14-pin needle cartridges. Used in professional healthcare settings by clinicians. Handpiece drives reciprocating needle cartridge to specific depths (0-2.0 mm). Output is mechanical skin penetration; intended to improve facial acne scar appearance. Benefits include controlled, consistent micro-injury to stimulate skin. Clinician adjusts penetration depth via device controls; output informs clinical treatment progression.

Clinical Evidence

No clinical data. Substantial equivalence established via bench testing, including penetration depth accuracy, structural integrity, electrical safety (IEC 60601-1), EMC (IEC 60601-1-2), biocompatibility (ISO 10993-1), sterilization validation (ISO 11135), and shelf-life/packaging validation.

Technological Characteristics

AC-powered motorized handpiece; 12-pin/14-pin EO-sterilized single-use cartridges. 33G needles, straight cylindrical body with conical tapered point. Adjustable depth 0-2.0 mm (0.20 mm increments). Embedded microprocessor control. Biocompatibility per ISO 10993-1. Shelf life 3 years.

Indications for Use

Indicated for adults aged 22 years or older for the treatment to improve the appearance of facial acne scars.

Regulatory Classification

Identification

A microneedling device for aesthetic use is a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use. This classification does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics.

Special Controls

The technical specifications and needle characteristics must be identified, including needle length, geometry, maximum penetration depth, and puncture rate. Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Accuracy of needle penetration depth and puncture rate; (ii) Safety features built into the device to protect against cross-contamination, including fluid ingress protection; and (iii) Identification of the maximum safe needle penetration depth for the device for the labeled indications for use. Performance data must demonstrate the sterility of the patient-contacting components of the device. Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the intended shelf life. Performance data must demonstrate the electrical safety and electromagnetic compatibility (EMC) of all electrical components of the device. Software verification, validation, and hazard analysis must be performed for all software components of the device. The patient-contacting components of the device must be demonstrated to be biocompatible. Performance data must validate the cleaning and disinfection instructions for reusable components of the device. Labeling must include the following: (i) Information on how to operate the device and its components and the typical course of treatment; (ii) A summary of the device technical parameters, including needle length, needle geometry, maximum penetration depth, and puncture rate; (iii) Validated methods and instructions for reprocessing of any reusable components: (iv) Disposal instructions; and (v) Shelf life. Patient labeling must be provided and must include: (i) Information on how the device operates and the typical course of treatment; (ii) The probable risks and benefits associated with use of the device; and (iii) Post-operative care instructions.

*Classification.* Class II (special controls). The special controls for this device are:(1) The technical specifications and needle characteristics must be identified, including needle length, geometry, maximum penetration depth, and puncture rate. (2) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Accuracy of needle penetration depth and puncture rate; (ii) Safety features built into the device to protect against cross-contamination, including fluid ingress protection; and (iii) Identification of the maximum safe needle penetration depth for the device for the labeled indications for use. (3) Performance data must demonstrate the sterility of the patient-contacting components of the device. (4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the intended shelf life. (5) Performance data must demonstrate the electrical safety and electromagnetic compatibility (EMC) of all electrical components of the device. (6) Software verification, validation, and hazard analysis must be performed for all software components of the device. (7) The patient-contacting components of the device must be demonstrated to be biocompatible. (8) Performance data must validate the cleaning and disinfection instructions for reusable components of the device. (9) Labeling must include the following: (i) Information on how to operate the device and its components and the typical course of treatment; (ii) A summary of the device technical parameters, including needle length, needle geometry, maximum penetration depth, and puncture rate; (iii) Validated methods and instructions for reprocessing of any reusable components; (iv) Disposal instructions; and (v) A shelf life. (10) Patient labeling must be provided and must include: (i) Information on how the device operates and the typical course of treatment; (ii) The probable risks and benefits associated with use of the device; and (iii) Postoperative care instructions.

Predicate Devices

• Dr.pen Microneedling System (K230420)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

May 13, 2026

Woorhi Mechatronics Co., Ltd.
Jungsu Lee
Official Correspondent
58, Sanbon-ro, 48beon-gil
Gunpo-si, Gyeonggi-do 15846
Republic Of Korea

Re: K252591
Trade/Device Name: Automatic Micro Needle System (CODE-X)
Regulation Number: 21 CFR 878.4430
Regulation Name: Microneedling device for aesthetic use
Regulatory Class: Class II
Product Code: QAI
Dated: April 12, 2026
Received: April 13, 2026

Dear Jungsu Lee:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K252591 - Jungsu Lee
Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}

K252591 - Jungsu Lee
Page 3

Sincerely,


For Jodie Giordano, Ph.D.
Assistant Director
DHT4B: Division of Infection Control and Plastic Surgery Devices
OHT4: Office of Surgical and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K252591 | |
| Device Name Automatic Micro Needle System (CODE-X) | |
| Indications for Use (Describe) | |
| The Automatic Micro Needle System (CODE-X) is a microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

510(K) Summary
K252591

Submitter

Woorhi Mechatronics Co., Ltd.
Woo Yong Woon
58, Sanbon-ro 48beon-gil, Gunpo-si, Gyeonggi-do, Republic of Korea
Email: [e-mail]
Tel.: [phone]

Device Information

- Trade Name: Automatic Micro Needle System (CODE-X)
- Common Name: Microneedling Device
- Classification Name: Microneedling Device For Aesthetic Use
- Product Code: QAI
- Panel: General and Plastic Surgery
- Regulation Number: 21 CFR 878.4430
- Device Class: Class II (Special Controls)
- Date Prepared: 04/09/2026

Predicate Devices:

Primary Predicate

- K230420, Dr.pen Microneedling System by GC AMERICA INC. (Guangzhou Ekai Electronic Technology Co., Ltd.)

Indication for Use:

The Automatic Micro Needle System is a microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older.

Device Description:

The CODE-X Automatic Micro Needle System is a motorized, AC-powered microneedling device designed to mechanically create microscopic channels in the epidermal and upper dermal layers of the skin for aesthetic use. The device delivers controlled microneedle penetration through a reciprocating needle cartridge driven by the motorized handpiece with embedded microprocessor control.

The system consists of the following components:

{5}

- Motorized handpiece (reusable) with adjustable needle depth control
- Sterile, single-use disposable microneedle cartridges (12-pin and 14-pin, EO sterilized)
- AC power adapter

The technical specifications of the device are as follows:

| Parameter | Specification |
| --- | --- |
| Power Source | AC Powered |
| Control Mechanism | Microprocessor (Embedded software) |
| Needle Configuration | 12-pin and 14-pin cartridges |
| Needle Gauge/Diameter | 33G (-0.2 mm) |
| Needle Shape/Geometry | Straight, cylindrical body with a conical tapered, sharp point |
| Needle Spacing | 2 mm spacing / 3.96³mm per needle |
| Needle Arrangement | Needles radially arranged |
| Adjustable Penetration Depth | 0 mm to 2.0 mm in 0.20 mm increments |
| Recommended Penetration Depth | 1.5 mm |
| Maximum Penetration Depth | 2.0 mm |
| Sterilization (Cartridge) | Ethylene Oxide (EO), single-use |
| Shelf Life | 3 years |
| Biocompatibility | According to ISO 10993-1 |
| Intended Use Environment | Professional healthcare setting (Rx) |

{6}

# Substantial Equivalence Comparison

| Characteristic | Proposed Device | Predicate Device | Comparison |
| --- | --- | --- | --- |
| Device Name | Automatic Micro Needle System (CODE-X) | Dr.pen Microneedling System | - |
| Manufacturer | Woorhi Mechatronics Co., Ltd. | GC AMERICA INC. | - |
| 510(k) Number | K252591 | K230420 | - |
| Regulatory Classification | Class II | Class II | - |
| Classification Name | Microneedling Device For Aesthetic Use | Microneedling Device For Aesthetic Use | - |
| Product Code | QAI | QAI | - |
| Indications for Use | A microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older. | A microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older. | Equivalence |
| Intended Location of Use | Skin (Face) | Skin (Face) | Equivalence |
| Power Source | AC Powered | AC Powered | Equivalence |
| Control Mechanism | Microprocessor (Embedded software) | Microprocessor (Embedded software) | Equivalence |
| Microneedling Cartridge | Sterile, Single use | Sterile, Single use | Equivalence |
| No. of Needles | 12-pin, 14-pin | 14-pin | Difference |
| Needle Shape/Geometry | Straight, cylindrical body with a conical tapered, sharp point | Straight, cylindrical body with a conical tapered, sharp point | Equivalence |
| Needle Spacing | 2 mm spacing / 3.96²mm per needle | 2 mm spacing / 3.96²mm per needle | Equivalence |
| Penetration Depth (Recommended) | 1.5 mm | 1.5 mm | Equivalence |
| Max Needle Setting | 2.0 mm | 2.0 mm | Equivalence |
| Penetration Depth Selection | 0 mm to 2.0 mm in 0.20 mm increments | 0 mm to 2.0 mm in 0.25 mm increments | Difference |
| Needle Arrangement | Needles radially arranged | Needles radially arranged | Equivalence |
| Sterility | Ethylene Oxide | Ethylene Oxide | Equivalence |
| Shelf Life | 3 years | 2 years | Difference |
| Clinical Performance | Not applicable | Not applicable | Equivalence |
| Biocompatibility | According to ISO 10993-1 | According to ISO 10993-1 | Equivalence |

# Substantial Equivalence: The Automatic Micro Needle System (CODE-X) is substantially equivalent to the Dr.pen Microneedling System (K230420) predicate device. The devices are under the same product code (QAI), have the same intended use/indication for use, same needle shape and arrangement, same material, recommended penetration depth, and sterilization method. The only technological differences are the number of needle options (additional 12-pin), penetration depth selection increment (0.20 mm vs. 0.25 mm), and shelf life (3 years vs. 2 years). These differences are either verified with performance data or are judged to have no significant impact on achieving the intended use.

{7}

# Non-Clinical Test Data

Below tests were performed on the subject device to demonstrate compliance with 21 CFR 878.4430 special controls:

- Penetration Depth Accuracy Testing (0.5, 1.0, 2.0 mm settings; n=10 per setting; all within ±5% tolerance)
- Maximum Safe Penetration Depth Verification (3 devices × 10 measurements = 30 total; all ≤ 2.1 mm; 95% CI [1.992, 2.008])
- Needle Structural Integrity Testing (1,000 penetration cycles; no fracture or deformation)
- Cartridge Attachment Security Testing (30 attach/detach cycles across 3 devices; no loosening)
- Electrical Safety Testing per IEC 60601-1
- EMC Testing per IEC 60601-1-2
- Biocompatibility Testing per ISO 10993-1
- EO Sterilization Validation per ISO 11135
- Packaging and Shelf Life Validation per ISO 11607 and ASTM D4169
- Reprocessing Validation for reusable handpiece
- Software Verification and Validation
- Human Factors Validation Testing

The results of the above tests demonstrate that the device performs as intended under anticipated conditions of use and meets the special controls requirements of 21 CFR 878.4430. Non-clinical performance data confirm that the device is substantially equivalent as the predicate device.

Clinical testing was not necessary to establish substantial equivalency of the device.

# Conclusion

The Automatic Micro Needle System (CODE-X) constitutes a substantially equivalent medical device, meeting all the declared requirements of its intended use. This device has the same intended use and fundamental scientific technology as its predicate device (Dr.pen Microneedling System, K230420). Therefore, the CODE-X Automatic Micro Needle System and its predicate are substantially equivalent.